The Best Stocks to Invest $1,000 in to Start the New Year Off Right

Alphabet is positioned to benefit from strong AI demand in 2026 as Google Cloud outgrows AWS and Azure, Gemini 3.0 enhances search monetization and agentic AI integration into Workspace could drive cloud adoption; Waymo remains a longer-term optionality. Vertex expects Alyftrek to boost profit margins despite product cannibalization, is expanding access to Journavx ( >170 million people) and has begun a rolling FDA submission for povetacicept for IgA nephropathy targeting completion in H1 2026, while a zimislecel Phase 3 dosing pause delays a planned filing. Enbridge offers defensive income and stability with a 5.8% forward dividend yield, 30 consecutive years of dividend increases and roughly $50 billion of growth opportunities through the end of the decade, nearly half tied to gas transmission.

Analysis

Market structure: AI acceleration is a clear winner for Alphabet (GOOG/GOOGL) — Gemini 3.0 and agentic AI should meaningfully lift Search engagement and Google Cloud share versus peers over 2026, while NVDA sees sustained GPU demand. Vertex (VRTX) benefits from multi-drug commercialization (Alyftrek, Journavx, povetacicept filing H1 2026) that shifts revenues from narrow CF dependence toward broader markets. Enbridge (ENB) is a defensive winner if macro slows — 5.8% forward yield and ~$50B growth backlog through 2030 support income and cash-flow stability.

Risk assessment: Key tail risks include targeted AI regulation/antitrust that could cap ad pricing or force structural change within 6–24 months, Vertex trial/manufacturing setbacks (zimislecel dosing pause) that can erase near-term upside, and a commodity shock or pipeline regulatory action hurting Enbridge. Immediate risks (days–weeks) center on earnings and FDA windows; medium term (months) on adoption of agentic AI by enterprises; long term (years) on Waymo monetization and structural ad-market shifts.

Trade implications: Favor conviction longs: core positions in GOOG (accumulate on <–5% moves), VRTX as a growth/biotech catalyst play into H1 2026, and ENB for 5–7% target annualized return + income. Use option structures: buy limited-cost VRTX call spreads into FDA windows and sell short-dated covered calls or cash-secured puts on ENB to enhance yield. Execute relative-value: long GOOG vs short AMZN/MSFT to express search/AI monetization versus general cloud exposure.

Key Decisions for Investors

• Establish a 3% portfolio long position in Alphabet (GOOG/GOOGL) now; average up to +1% on confirmed quarterly AI adoption beats, add up to +2% on >5% pullbacks; hedge with Jun‑2026 5% OTM puts sized to cap downside at ~3% portfolio risk.
• Initiate a 2% long position in Vertex (VRTX) and allocate 0.5% portfolio to a directional option: buy a H1‑H2 2026 call spread (buy near‑ATM, sell ~30% OTM) to capture upside from the povetacicept H1 2026 filing while limiting premium outlay.
• Establish a 3% core position in Enbridge (ENB) for income and downside protection; if unwilling to hold outright, sell 30–90 day cash‑secured puts at ~3–7% below current market to collect premium, and sell 1–2% covered calls quarterly to boost yield.
• Implement a 1.5% long GOOG / 1.5% short AMZN pair trade to express relative AI/search monetization strength; use equal notional sizing and tighten stops: close pair if differential moves against position by >8% or if GOOG AI metrics fall 10% vs prior quarter.
• Set concrete monitoring triggers: reassess VRTX exposure immediately if povetacicept rolling submission misses H1 2026 target or if zimislecel manufacturing pause extends >90 days; reduce ENB by 50% if 10‑yr UST yield rises >75bp from current level or if gas throughput falls >5% YoY.